Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)

NCT07011043 is registered in ClinicalTrials.gov with Climb Bio, Inc. as lead sponsor.

NCT NCT07011043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07011043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Climb Bio, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 10, 2025
Completion date
April 30, 2027
Enrollment
30 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus